Jill E Slansky
Overview
Explore the profile of Jill E Slansky including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
54
Citations
1502
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Elias A, Staley A, Fornier M, Vidal G, Alami V, Sams S, et al.
NPJ Breast Cancer
. 2024 Oct;
10(1):88.
PMID: 39368973
Most ER+ breast cancers (BC) express androgen receptors (AR). This randomized phase II trial of 4 months of neoadjuvant fulvestrant (Fulv) alone or with enzalutamide (Combo) assessed whether adding AR...
2.
Hay Z, Kim D, Cimons J, Knapp J, Kohler M, Quansah M, et al.
J Immunol
. 2024 Feb;
212(8):1381-1391.
PMID: 38416029
Granzymes are a family of proteases used by CD8 T cells to mediate cytotoxicity and other less-defined activities. The substrate and mechanism of action of many granzymes are unknown, although...
3.
Hay Z, Knapp J, Magallon R, OConnor B, Slansky J
Cancer Immunol Res
. 2023 Feb;
11(5):570-582.
PMID: 36787375
T-cell receptor (TCR) binding strength to peptide-MHC antigen complex influences numerous T-cell functions. However, the vast diversity of a polyclonal T-cell repertoire for even a single antigen greatly increases the...
4.
Camp F, Brunetti T, Williams M, Christenson J, Sreekanth V, Costello J, et al.
Cancers (Basel)
. 2022 Sep;
14(18).
PMID: 36139558
Antigenic differences formed by alterations in gene expression and alternative splicing are predicted in breast cancer cells undergoing epithelial to mesenchymal transition (EMT) and the reverse plasticity known as MET....
5.
Wang Y, Tsitsiklis A, Devoe S, Gao W, Chu H, Zhang Y, et al.
Front Immunol
. 2022 Aug;
13:847092.
PMID: 35967379
Certain CD8 T cell responses are particularly effective at controlling infection, as exemplified by elite control of HIV in individuals harboring HLA-B57. To understand the structural features that contribute to...
6.
Hay Z, Slansky J
Int J Mol Sci
. 2022 Feb;
23(3).
PMID: 35163755
Cytotoxic T lymphocytes, differentiated CD8+ T cells, use multiple mechanisms to mediate their function, including release of granules containing perforin and granzymes at target cells. Granzymes are a family of...
7.
Camp F, Slansky J
Pharmaceuticals (Basel)
. 2021 Oct;
14(10).
PMID: 34681217
Many immunotherapies rely on CD8+ effector T cells to recognize and kill cognate tumor cells. These T cell-based immunotherapies include adoptive cell therapy, such as CAR T cells or transgenic...
8.
Wei P, Jordan K, Buhrman J, Lei J, Deng H, Marrack P, et al.
Proc Natl Acad Sci U S A
. 2021 Jun;
118(23).
PMID: 34074778
Tumors frequently express unmutated self-tumor-associated antigens (self-TAAs). However, trial results using self-TAAs as vaccine targets against cancer are mixed, often attributed to deletion of T cells with high-affinity receptors (TCRs)...
9.
Williams M, Christenson J, ONeill K, Hafeez S, Ihle C, Spoelstra N, et al.
NPJ Breast Cancer
. 2021 May;
7(1):64.
PMID: 34045467
Many immune suppressive mechanisms utilized by triple negative breast cancer (TNBC) are regulated by oncogenic epithelial-to-mesenchymal transition (EMT). How TNBC EMT impacts innate immune cells is not fully understood. To...
10.
Marin-Jimenez J, Capasso A, Lewis M, Bagby S, Hartman S, Shulman J, et al.
Front Immunol
. 2021 Apr;
12:607282.
PMID: 33854497
Over the past decade, immunotherapies have revolutionized the treatment of cancer. Although the success of immunotherapy is remarkable, it is still limited to a subset of patients. More than 1500...